|
More
Consulting and Professional Services
Research Library
|
|
Technology Business Research, Inc
|
The following is information compiled from recently published Technology Business Research reports.
Excerpts included in this release are:
· NetApp – Computer Business Quarterly
· Deloitte Consulting – Professional Services Business Quarterly
· Computer Sciences Corp. – Professional Services Business Quarterly
· Alcatel-Lucent – Network Business Quarterly
|
|
|
Technology Business Research, Inc
|
Consulting and Systems integration business continues to be under pressure, as the market environment remains volatile. Consulting tends to fall in the discretionary budget category. In many instances, the offerings that consulting companies have are not critical to the survival of the business in the downturn. Thus, large ERP implementations, system and software upgrades, strategy consulting or ...
|
|
|
Technology Business Research, Inc
|
Throughout the economic downturn of 2008 and 2009, which dramatically impacted IT service spending, the Business Intelligence (BI) market remained a bright spot. In fact, many vendors experienced double-digit or even triple-digit growth of BI-related services in 2009, while experiencing revenue declines through the remainder of their portfolios.
Challenging economic times have created the need ...
|
|
|
APQC
|
"These definitions and key measures provide deeper detail about the processes outlined in category 4.0 Deliver Products and Services of APQC's Process Classification Framework (PCF). This reference can help organizations identify and align the activities that fall within each process. It also provides key performance indicators (KPIs) that APQC recommends for measuring and tracking the ...
|
|
|
Business Industrial Network
|
Discover the power of e-learning! RFID systems for pharmaceutical distributors to meet the new FDA regulations on drugs.
Abstract : The US FDA has decided to implement the “Pedigree provisions” of the Prescription Drugs Marketing Act after December 2006, when the current stay on it expires. There is a lot of concern that many pharma supply chain participants, may not be able to meet this ...
|
|
|
|
